Short answer
Aclaris Therapeutics, Inc. (ACRS) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $3M (down 24.1% year over year) with net income of −$15M.
Q3 2025 key financials · XBRL
- Revenue
- $3M
- −24.1% YoY · +85.6% QoQ
- Net income
- −$15M
- −92.6% YoY · +5.3% QoQ
- Operating margin
- -519.8%
- EPS (diluted)
- −$0.12
- −9.1% YoY · +7.7% QoQ
Source: XBRL data from the Aclaris Therapeutics, Inc. (ACRS) Q3 2025 10-Q on SEC EDGAR. USD.
Aclaris Therapeutics, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Partial MD&A provided; quarterly revenue and YoY change not disclosed
- Profitability and margin percentages not disclosed
- Segment or product-line performance not disclosed
- Cash position, operating cash flow, and capital deployment not disclosed
- Forward-looking statements subject to risks; no specific outlook or guidance provided
Risk Factors
- No risk-factors section provided in submitted excerpt
- Excerpt contains Item 5 trading-plan disclosure and Item 6 exhibits only
- No newly added, updated, regulatory, operational, or financial risks identifiable from provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aclaris Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.